Breast cancer is the most frequently diagnosed cancer in women under 60, and the second most diagnosed cancer in women over 60. While significant progress has been made in developing targeted therapies for breast cancer, advanced breast cancer continues to have high mortality, with poor 5-year survival rates. Thus, current therapies are insufficient in treating advanced stages of breast cancer; new treatments are sorely needed to address the complexity of advanced-stage breast cancer. Oncolytic virotherapy has been explored as a therapeutic approach capable of systemic administration, targeting cancer cells, and sparing normal tissue. In particular, oncolytic adenoviruses have been exploited as viral vectors due to their ease of manipulation, production, and demonstrated clinical safety profile. In this study, we engineered an oncolytic adenovirus to target the chemokine receptors CXCR4 and CXCR7. The overexpression of CXCR4 and CXCR7 is implicated in the initiation, survival, progress, and metastasis of breast cancer. Both receptors bind to the ligand, CXCL12 (SDF-1), which has been identified to play a crucial role in the metastasis of breast cancer cells. This study incorporated a T4 fibritin protein fused to CXCL12 into the tail domain of an adenovirus fiber to retarget the vector to the CXCR4 and CXCR7 chemokine receptors. We showed that the modified virus targets and infects CXCR4- and CXCR7- overexpressing breast cancer cells more efficiently than a wild-type control vector. In addition, the substitution of the wild-type fiber and knob with the modified chimeric fiber did not interfere with oncolytic capability. Overall, the results of this study demonstrate the feasibility of retargeting adenovirus vectors to chemokine receptor-positive tumors.
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34. https://doi.org/10.3322/caac.21551
O’Bryan, S.M. and Mathis, J.M. (2018) Oncolytic Virotherapy for Breast Cancer Treatment. Current Gene Therapy, 18, 192-205. https://doi.org/10.2174/1566523218666180910163805
Aghi, M. and Martuza, R.L. (2005) Oncolytic Viral Therapies—The Clinical Experience. Oncogene, 24, 7802-7816. https://doi.org/10.1038/sj.onc.1209037
Alemany, R., Balagué, C. and Curiel, D.T. (2000) Replicative Adenoviruses for Cancer Therapy. Nature Biotechnology, 18, 723-727. https://doi.org/10.1038/77283
Alemany, R. (2014) Oncolytic Adenoviruses in Cancer Treatment. Biomedicines, 2, 36-49. https://doi.org/10.3390/biomedicines2010036
Dong, X., Qu, W., Ma, S., Zhu, Z., Zheng, C., He, A., Karlsson, A., Xu, K. and Zheng, X. (2013) Potent Antitumoral Effects of Targeted Promoter-Driven Oncolytic Adenovirus Armed with Dm-dNK for Breast Cancer in vitro and in vivo. Cancer Letters, 328, 95-103. https://doi.org/10.1016/j.canlet.2012.09.003
Zhu, W., Zhang, H., Shi, Y., Song, M., Zhu, B. and Wei, L. (2013) Oncolytic Adenovirus Encoding Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Inhibits the Growth and Metastasis of Triple-Negative Breast Cancer. Cancer Biology and Therapy, 14, 1016-1023. https://doi.org/10.4161/cbt.26043
Hu, Z., Zhang, Z., Guise, T. and Seth, P. (2010) Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble Transforming Growth Factor-Beta Receptor II-Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model. Human Gene Therapy, 21, 1623-1629. https://doi.org/10.1089/hum.2010.018
Cody, J., Rivera, A.A., Lyons, G., Yang, S., Wang, M., Sarver, D., Wang, D., Selander, K., Kuo, H.-C., Meleth, S., Feng, X., Siegall, G. and Douglas, J. (2010) Arming a Replicating Adenovirus with Osteoprotegerin Reduces the Tumor Burden in a Murine Model of Osteolytic Bone Metastases of Breast Cancer. Cancer Gene Therapy, 17, 893-905. https://doi.org/10.1038/cgt.2010.47
Fang, L., Cheng, Q., Bai, J., Qi, Y.-D., Liu, J.-J., Li, L.-T. and Zheng, J.-N. (2013) An Oncolytic Adenovirus Expressing Interleukin-24 Enhances Antitumor Activities in Combination with Paclitaxel in Breast Cancer Cells. Molecular Medicine Reports, 8, 1416-1424. https://doi.org/10.3892/mmr.2013.1680
Xu, W., Yang, Y., Hu, Z., Head, M., Mangold, K.A., Sullivan, M., Wang, E., Saha, P., Gulukota, K., Helseth, D.L., Guise, T., Prabhkar, B.S., Kaul, K., Schreiber, H. and Seth, P. (2020) LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor Beta Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models. Human Gene Therapy, 31, 863-880. https://doi.org/10.1089/hum.2020.078
Virotherapy
Virus
Ranki, T., Särkioja, M., Hakkarainen, T., von Smitten, K., Kanerva, A. and Hemminki, A. (2007) Systemic Efficacy of Oncolytic Adenoviruses in Imagable Orthotopic Models of Hormone Refractory Metastatic Breast Cancer. International Journal of Cancer, 121, 165-174. https://doi.org/10.1002/ijc.22627
Bauerschmitz, G.J., Ranki, T., Kangasniemi, L., Ribacka, C., Eriksson, M., Porten, M., Herrmann, I., Ristimäki, A., Virkkunen, P., Tarkkanen, M., Hakkarainen, T., Kanerva, A., Rein, D., Pesonen, S. and Hemminki, A. (2008) Tissue-Specific Promoters Active in CD44+CD24-/Low Breast Cancer Cells. Cancer Research, 68, 5533-5539. https://doi.org/10.1158/0008-5472.CAN-07-5288
MacLeod, S.H., Elgadi, M.M., Bossi, G., Sankar, U., Pisio, A., Agopsowicz, K., Sharon, D., Graham, F.L. and Hitt, M.M. (2012) HER3 Targeting of Adenovirus by Fiber Modification Increases Infection of Breast Cancer Cells in Vitro, But Not following Intratumoral Injection in Mice. Cancer Gene Therapy, 19, 888-898. https://doi.org/10.1038/cgt.2012.79
Platonov, M.E., Borovjagin, A.V., Kaverina, N., Xiao, T., Kadagidze, Z., Lesniak, M., Baryshnikova, M. and Ulasov, I.V. (2018) KISS1 Tumor Suppressor Restricts Angiogenesis of Breast Cancer Brain Metastases and Sensitizes Them to Oncolytic Virotherapy in Vitro. Cancer Letters, 417, 75-88. https://doi.org/10.1016/j.canlet.2017.12.024
Garza-Morales, R., Gonzalez-Ramos, R., Chiba, A., de Oca-Luna, R., McNally, L.R., McMasters, K.M. and Gomez-Gutierrez, J.G. (2018) Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy in Vitro. Cancers, 10, 144. https://doi.org/10.3390/cancers10050144
Liikanen, I., Tahtinen, S., Guse, K., Gutmann, T., Savola, P., Oksanen, M., Kanerva, A. and Hemminki, A. (2016) Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics, 15, 2259-2269. https://doi.org/10.1158/1535-7163.MCT-15-0819
Zhang, Z., Krimmel, J., Zhang, Z., Hu, Z. and Seth, P. (2011) Systemic Delivery of a Novel Liver-Detargeted Oncolytic Adenovirus Causes Reduced Liver Toxicity but Maintains the Antitumor Response in a Breast Cancer Bone Metastasis Model. Human Gene Therapy, 22, 1137-1142. https://doi.org/10.1089/hum.2011.003
Kim, M., Zinn, K.R., Barnett, B.G., Sumerel, L.A., Krasnykh, V., Curiel, D.T. and Douglas, J.T. (2002) The Therapeutic Efficacy of Adenoviral Vectors for Cancer Gene Therapy Is Limited by a Low Level of Primary Adenovirus Receptors on Tumour Cells. European Journal of Cancer, 38, 1917-1926. https://doi.org/10.1016/S0959-8049(02)00131-4
Sirena, D., Lilienfeld, B., Eisenhut, M., Kälin, S., Boucke, K., Beerli, R.R., Vogt, L., Ruedl, C., Bachmann, M.F., Greber, U.F. and Hemmi, S. (2004) The Human Membrane Cofactor CD46 Is a Receptor for Species B Adenovirus Serotype 3. Journal of Virology, 78, 4454-4462. https://doi.org/10.1128/JVI.78.9.4454-4462.2004
Koski, A., Kangasniemi, L., Escutenaire, S., Pesonen, S., Cerullo, V., Diaconu, I., Nokisalmi, P., Raki, M., Rajecki, M., Guse, K., Ranki, T., Oksanen, M., Holm, S.-L., Haavisto, E., Karioja-Kallio, A., Laasonen, L., Partanen, K., Ugolini, M., Helminen, A., Karli, E., Hannuksela, P., Pesonen, S., Joensuu, T., Kanerva, A. and Hemminki, A. (2010) Treatment of Cancer Patients with a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF. Molecular Therapy, 18, 1874-1884. https://doi.org/10.1038/mt.2010.161
Pesonen, S., Diaconu, I., Cerullo, V., Escutenaire, S., Raki, M., Kangasniemi, L., Nokisalmi, P., Dotti, G., Guse, K., Laasonen, L., Partanen, K., Karli, E., Haavisto, E., Oksanen, M., Karioja-Kallio, A., Hannuksela, P., Holm, S.L., Kauppinen, S., Joensuu, T., Kanerva, A. and Hemminki, A. (2012) Integrin Targeted Oncolytic Adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for Treatment of Patients with Advanced Chemotherapy Refractory Solid Tumors. International Journal of Cancer, 130, 1937-1947. https://doi.org/10.1002/ijc.26216
Ranki, T., Kanerva, A., Ristimäki, A., Hakkarainen, T., Särkioja, M., Kangasniemi, L., Raki, M., Laakkonen, P., Goodison, S. and Hemminki, A. (2007) A Heparan Sulfate-Targeted Conditionally Replicative Adenovirus, Ad5.pk7-Δ24, for the Treatment of Advanced Breast Cancer. Gene Therapy, 14, 58-67. https://doi.org/10.1038/sj.gt.3302830
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., Barrera, J., Mohar, A., Verástegui, E. and Zlotnik, A. (2001) Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature, 410, 50-56. https://doi.org/10.1038/35065016
Balkwill, F. (2004) The Significance of Cancer Cell Expression of the Chemokine Receptor CXCR4. Seminars in Cancer Biology, 14, 171-179. https://doi.org/10.1016/j.semcancer.2003.10.003
Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J. and Springer, T.A. (1996) The Lymphocyte Chemoattractant SDF-1 Is a Ligand for LESTR/ Fusin and Blocks HIV-1 Entry. Nature, 382, 829-833. https://doi.org/10.1038/382829a0
Guo, F., Wang, Y., Liu, J., Mok, S.C., Xue, F. and Zhang, W. (2016) CXCL12/ CXCR4: A Symbiotic Bridge Linking Cancer Cells and Their Stromal Neighbors in Oncogenic Communication Networks. Oncogene, 35, 816-826. https://doi.org/10.1038/onc.2015.139
Hung, C.-S., Su, H.-Y., Liang, H.-H., Lai, C.-W., Chang, Y.-C., Ho, Y.-S., Wu, C.-H., Ho, J.-D., Wei, P.-L. and Chang, Y.-J. (2014) High-Level Expression of CXCR4 in Breast Cancer Is Associated with Early Distant and Bone Metastases. Tumor Biology, 35, 1581-1588. https://doi.org/10.1007/s13277-013-1218-9
Kang, H., Watkins, G., Douglas-Jones, A., Mansel, R.E. and Jiang, W.G. (2005) The Elevated Level of CXCR4 Is Correlated with Nodal Metastasis of Human Breast Cancer. The Breast, 14, 360-367. https://doi.org/10.1016/j.breast.2004.12.007
Wendel, C., Hemping-Bovenkerk, A., Krasnyanska, J., Mees, S., Kochetkova, M., Stoeppeler, S. and Haier, J. (2012) CXCR4/CXCL12 Participate in Extravasation of Metastasizing Breast Cancer Cells within the Liver in a Rat Model. PLoS ONE, 7, e30046. https://doi.org/10.1371/journal.pone.0030046
Balabanian, K., Lagane, B., Infantino, S., Chow, K.Y.C., Harriague, J., Moepps, B., Arenzana-Seisdedos, F., Thelen, M. and Bachelerie, F. (2005) The Chemokine SDF-1/ CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes. Journal of Biological Chemistry, 280, 35760-35766. https://doi.org/10.1074/jbc.M508234200
Luker, K.E., Lewin, S.A., Mihalko, L.A., Schmidt, B.T., Winkler, J.S., Coggins, N.L., Thomas, D.G. and Luker, G.D. (2012) Scavenging of CXCL12 by CXCR7 Promotes Tumor Growth and Metastasis of CXCR4-Positive Breast Cancer Cells. Oncogene, 31, 4750-4758. https://doi.org/10.1038/onc.2011.633
Stacer, A.C., Fenner, J., Cavnar, S.P., Xiao, A., Zhao, S., Chang, S.L., Salomonnson, A., Luker, K.E. and Luker, G.D. (2016) Endothelial CXCR7 Regulates Breast Cancer Metastasis. Oncogene, 35, 1716-1724. https://doi.org/10.1038/onc.2015.236
Hattermann, K., Holzenburg, E., Hans, F., Lucius, R., Held-Feindt, J. and Mentlein, R. (2014) Effects of the Chemokine CXCL12 and Combined Internalization of Its Receptors CXCR4 and CXCR7 in Human MCF-7 Breast Cancer Cells. Cell and Tissue Research, 357, 253-266. https://doi.org/10.1007/s00441-014-1823-y
Burns, J.M., Summers, B.C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M.E.T., Sunshine, M., Littman, D.R., Kuo, C.J., Wei, K., McMaster, B.E., Wright, K., Howard, M.C. and Schall, T.J. (2006) A Novel Chemokine Receptor for SDF-1 and I-TAC Involved in Cell Survival, Cell Adhesion, and Tumor Development. Journal of Experimental Medicine, 203, 2201-2213. https://doi.org/10.1084/jem.20052144
Miao, Z., Luker, K.E., Summers, B.C., Berahovich, R., Bhojani, M.S., Rehemtulla, A., Kleer, C.G., Essner, J.J., Nasevicius, A., Luker, G.D., Howard, M.C. and Schall, T.J. (2007) CXCR7 (RDC1) Promotes Breast and Lung Tumor Growth in vivo and Is Expressed on Tumor-Associated Vasculature. Proceedings of the National Academy of Sciences of the United States of America, 104, 15735-15740. https://doi.org/10.1073/pnas.0610444104
Bhatia, S., O’Bryan, S.M., Rivera, A.A., Curiel, D.T. and Mathis, J.M. (2016) CXCL12 Retargeting of an Adenovirus Vector to Cancer Cells Using a Bispecific Adapter. Oncolytic Virotherapy, 5, 99-113. https://doi.org/10.2147/OV.S112107
Verheije, M.H. and Rottier, P.J. (2012) Retargeting of Viruses to Generate Oncolytic Agents. Advances in Virology, 2012, Article ID: 798526. https://doi.org/10.1155/2012/798526
Smith, S.E., Mellor, P., Ward, A.K., Kendall, S., McDonald, M., Vizeacoumar, F.S., Vizeacoumar, F.J., Napper, S. and Anderson, D.H. (2017) Molecular Characterization of Breast Cancer Cell Lines through Multiple Omic Approaches. Breast Cancer Research, 19, Article No. 65. https://doi.org/10.1186/s13058-017-0855-0
Farkas, T., Yang, K., Le Pendu, J., Baines, J.D. and Cardin, R.D. (2019) The Coxsackievirus and Adenovirus Receptor, a Required Host Factor for Recovirus Infection, Is a Putative Enteric Calicivirus Receptor. Journal of Virology, 93, e00869-19. https://doi.org/10.1128/JVI.00869-19
Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P.L., Aldrich, W.A., Banerjee, P.T., Gillies, S.D., Curiel, D.T. and Krasnykh, V. (2003) Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells. Journal of Virology, 77, 11367-11377. https://doi.org/10.1128/JVI.77.21.11367-11377.2003
Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. and Curiel, D.T. (2001) Genetic Targeting of an Adenovirus Vector via Replacement of the Fiber Protein with the Phage T4 Fibritin. Journal of Virology, 75, 4176-4183. https://doi.org/10.1128/JVI.75.9.4176-4183.2001
Kashentseva, E.A., Seki, T., Curiel, D.T. and Dmitriev, I.P. (2002) Adenovirus Targeting to c-erbB-2 Oncoprotein by Single-Chain Antibody Fused to Trimeric Form of Adenovirus Receptor Ectodomain. Cancer Research, 62, 609-616.
He, T.-C., Zhou, S., da Costa, L., Yu, J., Kinzler, K. and Vogelstein, B. (1998) A Simplified System for Generating Recombinant Adenoviruses. Proceedings of the National Academy of Sciences of the United States of America, 95, 2509-2514. https://doi.org/10.1073/pnas.95.5.2509
Reeh, M., Bockhorn, M., Görgens, D., Vieth, M., Hoffmann, T., Simon, R., Izbicki, J.R., Sauter, G., Schumacher, U. and Anders, M. (2013) Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in Human Neoplasms: A Multitumour Array Analysis. British Journal of Cancer, 109, 1848-1858. https://doi.org/10.1038/bjc.2013.509
Papanikolopoulou, K., Forge, V., Goeltz, P. and Mitraki, A. (2004) Formation of Highly Stable Chimeric Trimers by Fusion of an Adenovirus Fiber Shaft Fragment with the Foldon Domain of Bacteriophage T4 Fibritin. Journal of Biological Chemistry, 279, 8991-8998. https://doi.org/10.1074/jbc.M311791200
van Erp, E., Kaliberova, L., Kaliberov, S. and Curiel, D.T. (2015) Retargeted Oncolytic Adenovirus Displaying a Single Variable Domain of Camelid Heavy-Chain-Only Antibody in a Fiber Protein. Molecular Therapy Oncolytics, 2, 15001. https://doi.org/10.1038/mto.2015.1
Sakr, H.I., Coleman, D.T., Cardelli, J.A. and Mathis, J.M. (2015) Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet Receptor. Oncolytic Virotherapy, 4, 119-132. https://doi.org/10.2147/OV.S87369
Stasiak, A.C. and Stehle, T. (2020) Human Adenovirus Binding to Host Cell Receptors: A Structural View. Medical Microbiology and Immunology, 209, 325-333. https://doi.org/10.1007/s00430-019-00645-2
Dechecchi, M.C., Melotti, P., Bonizzato, A., Santacatterina, M., Chilosi, M. and Cabrini, G. (2001) Heparan Sulfate Glycosaminoglycans Are Receptors Sufficient to Mediate the Initial Binding of Adenovirus Types 2 and 5. Journal of Virology, 75, 8772-8780. https://doi.org/10.1128/JVI.75.18.8772-8780.2001
Bayo-Puxan, N., Cascallo, M., Gros, A., Huch, M., Fillat, C. and Alemany, R. (2006) Role of the Putative Heparan Sulfate Glycosaminoglycan-Binding Site of the Adenovirus Type 5 Fiber Shaft on Liver Detargeting and Knob-Mediated Retargeting. Journal of General Virology, 87, 2487-2495. https://doi.org/10.1099/vir.0.81889-0
Lyle, C. and McCormick, F. (2010) Integrin αvβ5 Is a Primary Receptor for Adenovirus in CAR-Negative Cells. Virology Journal, 7, Article No. 148. https://doi.org/10.1186/1743-422X-7-148
Wang, B., Guo, P. and Auguste, D.T. (2015) Mapping the CXCR4 Receptor on Breast Cancer Cells. Biomaterials, 57, 161-168. https://doi.org/10.1016/j.biomaterials.2015.04.023
Sivrikoz, O.N, Doganay, L., Sivrikoz, U.K, Karaarslan, S. and Sanal, S.M. (2013) Distribution of CXCR4 and γ-Catenin Expression Pattern in Breast Cancer Subtypes and Their Relationship to Axillary Nodal Involvement. Polish Journal of Pathology, 64, 253-259. https://doi.org/10.5114/pjp.2013.39333
Zhang, M., Liu, H.X., Teng, X.D., Wang, H., Cui, J., Jia, S., Gu, X. and Li, Z. (2012) The Differences in CXCR4 Protein Expression Are Significant for the Five Molecular Subtypes of Breast Cancer. Ultrastructural Pathology, 36, 381-386. https://doi.org/10.3109/01913123.2012.728687
Chen, H.W., Du, C.W., Wei, X., Khoo, U.S. and Zhang, G. (2013) Cytoplasmic CXCR4 High-Expression Exhibits Distinct Poor Clinicopathological Characteristics and Predicts Poor Prognosis in Triple-Negative Breast Cancer. Current Molecular Medicine, 13, 410-416. https://doi.org/10.2174/156652413805076803
Wu, W., Qian, L., Chen, X. and Ding, B. (2015) Prognostic Significance of CXCL12, CXCR4, and CXCR7 in Patients with Breast Cancer. International Journal of Clinical and Experimental Pathology, 8, 13217-13224.
Zlotnik, A. (2006) Chemokines and Cancer. International Journal of Cancer, 119, 2026-2029. https://doi.org/10.1002/ijc.22024
Boldajipour, B., Mahabaleshwar, S., Kardash, E., Reichman-Fried, M., Blaser, H., Minina, S., Wilson, D., Xu, Q. and Raz, E. (2008) Control of Chemokine-Guided Cell Migration by Ligand Sequestration. Cell, 132, 463-473. https://doi.org/10.1016/j.cell.2007.12.034
Luker, K.E., Steele, J.M., Mihalko, L.A., Ray, P. and Luker, G.D. (2010) Constitutive and Chemokine-Dependent Internalization and Recycling of CXCR7 in Breast Cancer Cells to Degrade Chemokine Ligands. Oncogene, 29, 4599-4610. https://doi.org/10.1038/onc.2010.212
Salazar, N., Munoz, D., Kallifatidis, G., Singh, R., Jorda, M. and Lokeshwar, B.L. (2014) The Chemokine Receptor CXCR7 Interacts with EGFR to Promote Breast Cancer Cell Proliferation. Molecular Cancer, 13, Article No. 198. https://doi.org/10.1186/1476-4598-13-198
Tang, X., Li, X., Li, Z., Liu, Y., Yao, L., Song, S., Yang, H. and Li, C. (2016) Downregulation of CXCR7 Inhibits Proliferative Capacity and Stem Cell-Like Properties in Breast Cancer Stem Cells. Tumor Biology, 37, 13425-13433. https://doi.org/10.1007/s13277-016-5180-1
Wu, Y.-C., Tang, S.-H., Sung, G.-H. and Sun, K.-H. (2016) CXCR7 Mediates TGFbeta1-Promoted EMT and Tumor-Initiating Features in Lung Cancer. Oncogene, 35, 2123-2132. https://doi.org/10.1038/onc.2015.274
Heinrich, E.L., Lee, W., Lu, J., Lowy, A.M. and Kim, J. (2012) Chemokine CXCL12 Activates Dual CXCR4 and CXCR7-Mediated Signaling Pathways in Pancreatic Cancer Cells. Journal of Translational Medicine, 10, Article No. 68. https://doi.org/10.1186/1479-5876-10-68
Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F. and Lagane, B. (2009) CXCR7 Heterodimerizes with CXCR4 and Regulates CXCL12-Mediated G Protein Signaling. Blood, 113, 6085-6093. https://doi.org/10.1182/blood-2008-12-196618
Décaillot, F.M., Kazmi, M.A., Lin, Y., Ray-Saha, S., Sakmar, T.P. and Sachdev, P. (2011) CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration. Journal of Biological Chemistry, 286, 32188-32197. https://doi.org/10.1074/jbc.M111.277038
Koodie, L., Robertson, M.G., Chandrashekar, M., Ruth, G., Dunning, M., Bianco, R.W. and Davydova, J. (2019) Rodents versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses. Cancers, 11, 198. https://doi.org/10.3390/cancers11020198
Thomas, M.A., Spencer, J.F., Regina, M.C., Dhar, D., Tollefson, A.E., Toth, K. and Wold, W. (2006) Syrian Hamster as a Permissive Immunocompetent Animal Model for the Study of Oncolytic Adenovirus Vectors. Cancer Research, 66, 1270-1276. https://doi.org/10.1158/0008-5472.CAN-05-3497
Wold, W. and Toth, K. (2012) Chapter Three-Syrian Hamster as an Animal Model to Study Oncolytic Adenoviruses and to Evaluate the Efficacy of Antiviral Compounds. In: David, T.C. and Paul, B.F. Eds., Advance in Cancer Research, Vol. 115, Elsevier, Amsterdam, 69-92. https://doi.org/10.1016/B978-0-12-398342-8.00003-3
O’Bryan, S.M. (2019) Generation of an Oncolytic Adenovirus Targeting the CXCR4 and CXCR7 Chemokine Receptors in Breast Cancer. LSU Doctoral Dissertations, 5035, Louisiana State University and Agricultural and Mechanical College, Baton Rouge. https://digitalcommons.lsu.edu/gradschool_dissertations/5035